Published in Drug Alcohol Depend on January 13, 2010
Association of OPRM1 and COMT single-nucleotide polymorphisms with hospital length of stay and treatment of neonatal abstinence syndrome. JAMA (2013) 2.34
Opioid receptors: distinct roles in mood disorders. Trends Neurosci (2012) 1.31
Human Mu Opioid Receptor (OPRM1 A118G) polymorphism is associated with brain mu-opioid receptor binding potential in smokers. Proc Natl Acad Sci U S A (2011) 1.29
Opiate addiction and cocaine addiction: underlying molecular neurobiology and genetics. J Clin Invest (2012) 1.26
A common single nucleotide polymorphism A118G of the μ opioid receptor alters its N-glycosylation and protein stability. Biochem J (2012) 1.06
The genetics of the opioid system and specific drug addictions. Hum Genet (2012) 1.04
Individualised treatment in alcohol-dependent patients. Eur Arch Psychiatry Clin Neurosci (2010) 1.00
The multiple facets of opioid receptor function: implications for addiction. Curr Opin Neurobiol (2013) 0.99
Challenges for opioid receptor nomenclature: IUPHAR Review 9. Br J Pharmacol (2014) 0.99
Reduced expression of the μ opioid receptor in some, but not all, brain regions in mice with OPRM1 A112G. Neuroscience (2012) 0.98
Effects of the Mu opioid receptor polymorphism (OPRM1 A118G) on pain regulation, placebo effects and associated personality trait measures. Neuropsychopharmacology (2014) 0.94
Pharmacological consequence of the A118G μ opioid receptor polymorphism on morphine- and fentanyl-mediated modulation of Ca²⁺ channels in humanized mouse sensory neurons. Anesthesiology (2011) 0.92
Is the rodent maternal separation model a valid and effective model for studies on the early-life impact on ethanol consumption? Psychopharmacology (Berl) (2013) 0.90
Individual differences in morphine and butorphanol analgesia: a laboratory pain study. Pain Med (2011) 0.89
ELK1 transcription factor linked to dysregulated striatal mu opioid receptor signaling network and OPRM1 polymorphism in human heroin abusers. Biol Psychiatry (2013) 0.87
Association of the OPRM1 Variant rs1799971 (A118G) with Non-Specific Liability to Substance Dependence in a Collaborative de novo Meta-Analysis of European-Ancestry Cohorts. Behav Genet (2015) 0.86
Associations of OPRM1 A118G and alcohol sensitivity with intravenous alcohol self-administration in young adults. Addict Biol (2014) 0.86
The human μ-opioid receptor gene polymorphism (A118G) is associated with head pain severity in a clinical cohort of female migraine with aura patients. J Headache Pain (2012) 0.85
Mouse model of the OPRM1 (A118G) polymorphism: differential heroin self-administration behavior compared with wild-type mice. Neuropsychopharmacology (2015) 0.85
Modeling socially anhedonic syndromes: genetic and pharmacological manipulation of opioid neurotransmission in mice. Transl Psychiatry (2012) 0.83
Neuropeptides as mediators of the early-life impact on the brain; implications for alcohol use disorders. Front Mol Neurosci (2012) 0.83
Translational genetic approaches to substance use disorders: bridging the gap between mice and humans. Hum Genet (2011) 0.83
μ-Opioid receptor availability in the amygdala is associated with smoking for negative affect relief. Psychopharmacology (Berl) (2012) 0.82
Brain region- and sex-specific alterations in DAMGO-stimulated [(35) S]GTPγS binding in mice with Oprm1 A112G. Addict Biol (2012) 0.82
Overview and historical perspective of four papers presented on research related to the endogenous opioid system. Drug Alcohol Depend (2010) 0.82
Common Polymorphisms in the Age of Research Domain Criteria (RDoC): Integration and Translation. Biol Psychiatry (2015) 0.82
Endogenous Opioids: The Downside of Opposing Stress. Neurobiol Stress (2015) 0.81
Functional polymorphism of the mu-opioid receptor gene (OPRM1) influences reinforcement learning in humans. PLoS One (2011) 0.81
Cellular signalling of non-synonymous single-nucleotide polymorphisms of the human μ-opioid receptor (OPRM1). Br J Pharmacol (2014) 0.81
μ-Opioid receptor gene (OPRM1) polymorphism A118G: lack of association in Finnish populations with alcohol dependence or alcohol consumption. Alcohol Alcohol (2013) 0.81
Association of genetic variation in pharmacodynamic factors with methadone dose required for effective treatment of opioid addiction. Pharmacogenomics (2013) 0.80
COMT Val158Met, BDNF Val66Met, and OPRM1 Asn40Asp and methamphetamine dependence treatment response: preliminary investigation. J Clin Psychopharmacol (2012) 0.80
Neuroimaging in psychiatric pharmacogenetics research: the promise and pitfalls. Neuropsychopharmacology (2013) 0.80
Variations in opioid receptor genes in neonatal abstinence syndrome. Drug Alcohol Depend (2015) 0.80
Utility of genetically modified mice for understanding the neurobiology of substance use disorders. Hum Genet (2011) 0.79
Pharmacogenetic approaches in the treatment of alcohol use disorders: addressing clinical utility and implementation thresholds. Addict Sci Clin Pract (2014) 0.79
Buprenorphine-mediated transition from opioid agonist to antagonist treatment: state of the art and new perspectives. Curr Drug Abuse Rev (2012) 0.79
Subjective health complaints in patients with lumbar radicular pain and disc herniation are associated with a sex - OPRM1 A118G polymorphism interaction: a prospective 1-year observational study. BMC Musculoskelet Disord (2014) 0.78
Combined effect of common gene variants on response to drug withdrawal therapy in medication overuse headache. Eur J Clin Pharmacol (2014) 0.78
Buprenorphine signalling is compromised at the N40D polymorphism of the human μ opioid receptor in vitro. Br J Pharmacol (2014) 0.78
A prospective study of genetic factors, human laboratory phenotypes, and heavy drinking in late adolescence. Addict Biol (2016) 0.78
Morphine-induced internalization of the L83I mutant of the rat μ-opioid receptor. Br J Pharmacol (2014) 0.77
Mouse model of OPRM1 (A118G) polymorphism increases sociability and dominance and confers resilience to social defeat. J Neurosci (2015) 0.77
Sweet taste pleasantness is modulated by morphine and naltrexone. Psychopharmacology (Berl) (2016) 0.76
Endogenous opioids: opposing stress with a cost. F1000Prime Rep (2015) 0.75
Opioids in pregnancy and neonatal abstinence syndrome. Semin Perinatol (2015) 0.75
Association between Opioid Receptor mu 1 (OPRM1) Gene Polymorphisms and Tobacco and Alcohol Consumption in a Spanish Population. Bosn J Basic Med Sci (2015) 0.75
Mouse model of OPRM1 (A118G) polymorphism has altered hippocampal function. Neuropharmacology (2015) 0.75
A cis-eQTL in OPRM1 is Associated with Subjective Response to Alcohol and Alcohol Use. Alcohol Clin Exp Res (2017) 0.75
Neonatal abstinence syndrome: Pharmacologic strategies for the mother and infant. Semin Perinatol (2016) 0.75
Functional characteristics of the naked mole rat μ-opioid receptor. PLoS One (2013) 0.75
Introduction to the College on Problems of Drug Dependence special issue: contemporary advances in opioid neuropharmacology. Drug Alcohol Depend (2010) 0.75
A6V polymorphism of the human μ-opioid receptor decreases signalling of morphine and endogenous opioids in vitro. Br J Pharmacol (2015) 0.75
Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc Natl Acad Sci U S A (1988) 11.96
Naltrexone in the treatment of alcohol dependence. Arch Gen Psychiatry (1992) 5.48
Is there a common molecular pathway for addiction? Nat Neurosci (2005) 5.43
Opioids excite dopamine neurons by hyperpolarization of local interneurons. J Neurosci (1992) 5.27
An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study. Arch Gen Psychiatry (2008) 4.91
Single-nucleotide polymorphism in the human mu opioid receptor gene alters beta-endorphin binding and activity: possible implications for opiate addiction. Proc Natl Acad Sci U S A (1998) 4.67
Why rejection hurts: a common neural alarm system for physical and social pain. Trends Cogn Sci (2004) 3.95
A potent and selective endogenous agonist for the mu-opiate receptor. Nature (1997) 3.87
A functional polymorphism of the mu-opioid receptor gene is associated with naltrexone response in alcohol-dependent patients. Neuropsychopharmacology (2003) 3.66
Naltrexone and coping skills therapy for alcohol dependence. A controlled study. Arch Gen Psychiatry (1992) 3.55
Allelic expression imbalance of human mu opioid receptor (OPRM1) caused by variant A118G. J Biol Chem (2005) 3.53
Opiate receptor knockout mice define mu receptor roles in endogenous nociceptive responses and morphine-induced analgesia. Proc Natl Acad Sci U S A (1997) 3.26
Brain circuitry and the reinstatement of cocaine-seeking behavior. Psychopharmacology (Berl) (2003) 3.24
Human opioid receptor A118G polymorphism affects intravenous patient-controlled analgesia morphine consumption after total abdominal hysterectomy. Anesthesiology (2006) 3.09
Drug dependence: stress and dysregulation of brain reward pathways. Drug Alcohol Depend (1998) 2.94
Pharmacological characterization of the cloned kappa-, delta-, and mu-opioid receptors. Mol Pharmacol (1994) 2.70
Effects of naltrexone on alcohol sensitivity and genetic moderators of medication response: a double-blind placebo-controlled study. Arch Gen Psychiatry (2007) 2.28
A polymorphism of the mu-opioid receptor gene (OPRM1) and sensitivity to the effects of alcohol in humans. Alcohol Clin Exp Res (2004) 2.25
The A118G single nucleotide polymorphism of the mu-opioid receptor gene (OPRM1) is associated with pressure pain sensitivity in humans. J Pain (2005) 2.23
Effect of the A118G polymorphism on binding affinity, potency and agonist-mediated endocytosis, desensitization, and resensitization of the human mu-opioid receptor. J Neurochem (2004) 2.07
Haplotypes at the OPRM1 locus are associated with susceptibility to substance dependence in European-Americans. Am J Med Genet B Neuropsychiatr Genet (2003) 2.07
Association of an Asn40Asp (A118G) polymorphism in the mu-opioid receptor gene with substance dependence: a meta-analysis. Drug Alcohol Depend (2006) 1.96
Association between two mu-opioid receptor gene (OPRM1) haplotype blocks and drug or alcohol dependence. Hum Mol Genet (2006) 1.93
Opioid receptor gene (OPRM1, OPRK1, and OPRD1) variants and response to naltrexone treatment for alcohol dependence: results from the VA Cooperative Study. Alcohol Clin Exp Res (2007) 1.86
Candidate genes for alcohol dependence: a review of genetic evidence from human studies. Alcohol Clin Exp Res (2003) 1.85
The polymorphism A118G of the human mu-opioid receptor gene decreases the pupil constrictory effect of morphine-6-glucuronide but not that of morphine. Pharmacogenetics (2002) 1.80
The single nucleotide polymorphism A118G alters functional properties of the human mu opioid receptor. J Neurochem (2007) 1.78
The 118 A > G polymorphism in the human mu-opioid receptor gene may increase morphine requirements in patients with pain caused by malignant disease. Acta Anaesthesiol Scand (2004) 1.77
Mouse model of OPRM1 (A118G) polymorphism has sex-specific effects on drug-mediated behavior. Proc Natl Acad Sci U S A (2009) 1.76
The functional mu opioid receptor (OPRM1) Asn40Asp variant predicts short-term response to nicotine replacement therapy in a clinical trial. Pharmacogenomics J (2004) 1.74
Variation in the mu-opioid receptor gene (OPRM1) is associated with dispositional and neural sensitivity to social rejection. Proc Natl Acad Sci U S A (2009) 1.74
Association of ABCB1/MDR1 and OPRM1 gene polymorphisms with morphine pain relief. Clin Pharmacol Ther (2007) 1.72
Mu opioid receptor gene variants: lack of association with alcohol dependence. Mol Psychiatry (1998) 1.72
Exploring joint effects of genes and the clinical efficacy of morphine for cancer pain: OPRM1 and COMT gene. Pain (2006) 1.72
Opioids and alcoholism. Physiol Behav (2004) 1.67
mu-Opioid receptor knockout mice do not self-administer alcohol. J Pharmacol Exp Ther (2000) 1.67
Increased attributable risk related to a functional mu-opioid receptor gene polymorphism in association with alcohol dependence in central Sweden. Neuropsychopharmacology (2005) 1.66
Genetics of two mu opioid receptor gene (OPRM1) exon I polymorphisms: population studies, and allele frequencies in alcohol- and drug-dependent subjects. Mol Psychiatry (1999) 1.66
A single nucleotide polymorphic mutation in the human mu-opioid receptor severely impairs receptor signaling. J Biol Chem (2000) 1.65
A118G single nucleotide polymorphism of human mu-opioid receptor gene influences pain perception and patient-controlled intravenous morphine consumption after intrathecal morphine for postcesarean analgesia. Anesthesiology (2008) 1.59
Relatively strong automatic appetitive action-tendencies in male carriers of the OPRM1 G-allele. Genes Brain Behav (2008) 1.59
Expansion of the human mu-opioid receptor gene architecture: novel functional variants. Hum Mol Genet (2008) 1.59
Substantial attributable risk related to a functional mu-opioid receptor gene polymorphism in association with heroin addiction in central Sweden. Mol Psychiatry (2004) 1.56
Variation at the mu-opioid receptor gene (OPRM1) influences attachment behavior in infant primates. Proc Natl Acad Sci U S A (2008) 1.56
Association of mu-opioid receptor gene polymorphism (A118G) with variations in morphine consumption for analgesia after total knee arthroplasty. Acta Anaesthesiol Scand (2006) 1.54
Moderators of naltrexone's effects on drinking, urge, and alcohol effects in non-treatment-seeking heavy drinkers in the natural environment. Alcohol Clin Exp Res (2007) 1.53
Genetic predictors of the clinical response to opioid analgesics: clinical utility and future perspectives. Clin Pharmacokinet (2004) 1.51
Polymorphisms affecting gene transcription and mRNA processing in pharmacogenetic candidate genes: detection through allelic expression imbalance in human target tissues. Pharmacogenet Genomics (2008) 1.51
Association of a functional polymorphism in the mu-opioid receptor gene with alcohol response and consumption in male rhesus macaques. Arch Gen Psychiatry (2007) 1.50
Mu-opioid receptor and CREB activation are required for nicotine reward. Neuron (2005) 1.45
Differential neural response to alcohol priming and alcohol taste cues is associated with DRD4 VNTR and OPRM1 genotypes. Alcohol Clin Exp Res (2008) 1.43
Mu opioid receptor gene polymorphisms and heroin dependence in Asian populations. Neuroreport (2003) 1.42
Amino acid 49 polymorphisms of the human beta1-adrenergic receptor affect agonist-promoted trafficking. J Cardiovasc Pharmacol (2002) 1.38
Association of OPRM1 A118G variant with the relative reinforcing value of nicotine. Psychopharmacology (Berl) (2006) 1.37
Mu opioid receptor A118G polymorphism in association with striatal opioid neuropeptide gene expression in heroin abusers. Proc Natl Acad Sci U S A (2006) 1.37
Environmental and genetic factors associated with morphine response in the postoperative period. Clin Pharmacol Ther (2006) 1.37
A functional polymorphism of the mu-opioid receptor gene (OPRM1) influences cue-induced craving for alcohol in male heavy drinkers. Alcohol Clin Exp Res (2007) 1.33
Attenuation of nicotine-induced antinociception, rewarding effects, and dependence in mu-opioid receptor knock-out mice. J Neurosci (2002) 1.32
Association between the cortisol response to opioid blockade and the Asn40Asp polymorphism at the mu-opioid receptor locus (OPRM1). Am J Med Genet B Neuropsychiatr Genet (2003) 1.29
The mu-opioid receptor gene and smoking initiation and nicotine dependence. Behav Brain Funct (2006) 1.28
The mu-opioid receptor gene polymorphism 118A>G depletes alfentanil-induced analgesia and protects against respiratory depression in homozygous carriers. Pharmacogenet Genomics (2006) 1.27
The mu-opioid receptor polymorphism A118G predicts cortisol responses to naloxone and stress. Neuropsychopharmacology (2006) 1.26
Ethanol consumption and reward are decreased in mu-opiate receptor knockout mice. Psychopharmacology (Berl) (2001) 1.26
A genetic association study of the mu opioid receptor and severe opioid dependence. Psychiatr Genet (2003) 1.25
A mu-opioid receptor single nucleotide polymorphism in rhesus monkey: association with stress response and aggression. Mol Psychiatry (2004) 1.25
Genetic moderators of naltrexone's effects on alcohol cue reactivity. Alcohol Clin Exp Res (2006) 1.24
Ethnicity and OPRM variant independently predict pain perception and patient-controlled analgesia usage for post-operative pain. Mol Pain (2009) 1.24
Polymorphism of mu-opioid receptor gene (OPRM1:c.118A>G) does not protect against opioid-induced respiratory depression despite reduced analgesic response. Anesthesiology (2005) 1.23
Endogenous opioids and addiction to alcohol and other drugs of abuse. Curr Top Med Chem (2004) 1.23
Association between mu opioid receptor gene polymorphisms and Chinese heroin addicts. Neuroreport (2001) 1.22
Genetic variability of the mu-opioid receptor influences intrathecal fentanyl analgesia requirements in laboring women. Pain (2008) 1.22
Dopamine and opioid gene variants are associated with increased smoking reward and reinforcement owing to negative mood. Behav Pharmacol (2008) 1.22
Brain mechanisms of drug reward and euphoria. Psychiatr Med (1985) 1.21
Candidate genes for nicotine dependence via linkage, epistasis, and bioinformatics. Am J Med Genet B Neuropsychiatr Genet (2004) 1.21
Linkage analysis of smoking initiation and quantity in Dutch sibling pairs. Pharmacogenomics J (2004) 1.20
Analgesic requirements after major abdominal surgery are associated with OPRM1 gene polymorphism genotype and haplotype. Pharmacogenomics (2008) 1.19
Alcoholism: genes and mechanisms. Pharmacogenomics (2004) 1.17
A genetic association study of the functional A118G polymorphism of the human mu-opioid receptor gene in patients with acute and chronic pain. Anesth Analg (2006) 1.15
The opioid system in alcohol and drug dependence: family-based association study. Am J Med Genet B Neuropsychiatr Genet (2007) 1.14
Suppression of alcohol preference by naltrexone in the rhesus macaque: a critical role of genetic variation at the micro-opioid receptor gene locus. Biol Psychiatry (2010) 1.14
Opioid receptor and peptide gene polymorphisms: potential implications for addictions. Eur J Pharmacol (2000) 1.12
OPRM1 Asn40Asp predicts response to naltrexone treatment: a haplotype-based approach. Alcohol Clin Exp Res (2008) 1.12
Sequence variations in the mu-opioid receptor gene (OPRM1) associated with human addiction to heroin. Hum Mutat (2002) 1.11
Evaluation of OPRM1 variants in heroin dependence by family-based association testing and meta-analysis. Drug Alcohol Depend (2007) 1.10
A common human micro-opioid receptor genetic variant diminishes the receptor signaling efficacy in brain regions processing the sensory information of pain. J Biol Chem (2008) 1.10
A micro opioid receptor gene polymorphism (A118G) and naltrexone treatment response in adherent Korean alcohol-dependent patients. Psychopharmacology (Berl) (2008) 1.10
Association of the mu-opioid receptor gene with smoking cessation. Pharmacogenomics J (2007) 1.09
Pharmacogenomics of alcohol response and addiction. Am J Pharmacogenomics (2003) 1.09
Stress responsivity, addiction, and a functional variant of the human mu-opioid receptor gene. Mol Interv (2007) 1.08
Endogenous opioid receptor genes and alcohol dependence among Taiwanese Han. Alcohol Clin Exp Res (2004) 1.07
Single nucleotide polymorphisms in the human mu opioid receptor gene alter basal G protein coupling and calmodulin binding. J Biol Chem (2001) 1.06
A functional polymorphism within the mu-opioid receptor gene and risk for abuse of alcohol and other substances. Mol Psychiatry (2002) 1.06
Association of a functional mu-opioid receptor allele (+118A) with alcohol dependency. Am J Med Genet (1999) 1.06
Targeting treatments for alcohol dependence: the pharmacogenetics of naltrexone. Addict Biol (2006) 1.06
Association of functional opioid receptor genotypes with alcohol dependence in Koreans. Alcohol Clin Exp Res (2004) 1.06
Nonreplication of association between mu-opioid-receptor gene (OPRM1) A118G polymorphism and substance dependence. Am J Med Genet (2001) 1.05
Population-specific effects of the Asn40Asp polymorphism at the mu-opioid receptor gene (OPRM1) on HPA-axis activation. Pharmacogenet Genomics (2007) 1.05
Endogenous opiates: 1999. Peptides (2000) 1.05
A118g polymorphism in mu opioid receptor gene (oprm1): association with opiate addiction in subjects of Indian origin. J Integr Neurosci (2007) 1.03
Attenuation of methamphetamine-induced behavioral sensitization in mice by systemic administration of naltrexone. Brain Res Bull (2005) 1.02
Mouse model of OPRM1 (A118G) polymorphism has sex-specific effects on drug-mediated behavior. Proc Natl Acad Sci U S A (2009) 1.76
cAMP response element-binding protein is essential for the upregulation of brain-derived neurotrophic factor transcription, but not the behavioral or endocrine responses to antidepressant drugs. J Neurosci (2002) 1.71
cAMP response element-binding protein is required for stress but not cocaine-induced reinstatement. J Neurosci (2004) 1.59
Rett syndrome mutation MeCP2 T158A disrupts DNA binding, protein stability and ERP responses. Nat Neurosci (2011) 1.53
Mu-opioid receptor and CREB activation are required for nicotine reward. Neuron (2005) 1.45
Dysregulated editing of serotonin 2C receptor mRNAs results in energy dissipation and loss of fat mass. J Neurosci (2008) 1.41
Genetic evidence for a role of CREB in sustained cortical arousal. J Neurophysiol (2003) 1.37
Strain-dependent antidepressant-like effects of citalopram in the mouse tail suspension test. Psychopharmacology (Berl) (2005) 1.37
Human Mu Opioid Receptor (OPRM1 A118G) polymorphism is associated with brain mu-opioid receptor binding potential in smokers. Proc Natl Acad Sci U S A (2011) 1.29
Antidepressant action: to the nucleus and beyond. Trends Pharmacol Sci (2005) 1.24
Nicotinic partial agonists varenicline and sazetidine-A have differential effects on affective behavior. J Pharmacol Exp Ther (2010) 1.24
cAMP response element-binding protein deficiency allows for increased neurogenesis and a rapid onset of antidepressant response. J Neurosci (2007) 1.23
The role of the Asn40Asp polymorphism of the mu opioid receptor gene (OPRM1) on alcoholism etiology and treatment: a critical review. Alcohol Clin Exp Res (2011) 1.18
Endocrine and gene expression changes following forced swim stress exposure during cocaine abstinence in mice. Psychopharmacology (Berl) (2008) 1.14
Parallel anxiolytic-like effects and upregulation of neuronal nicotinic acetylcholine receptors following chronic nicotine and varenicline. Nicotine Tob Res (2010) 1.13
Making a bad thing worse: adverse effects of stress on drug addiction. J Clin Invest (2008) 1.13
Molecular and genetic substrates linking stress and addiction. Brain Res (2009) 1.11
Activating transcription factor 1 and CREB are important for cell survival during early mouse development. Mol Cell Biol (2002) 1.11
NAC1 regulates the recruitment of the proteasome complex into dendritic spines. J Neurosci (2007) 1.08
Effects of the histone deacetylase inhibitor sodium butyrate in models of depression and anxiety. Neuropharmacology (2009) 1.06
Ventral tegmental afferents in stress-induced reinstatement: the role of cAMP response element-binding protein. J Neurosci (2010) 1.06
A common single nucleotide polymorphism A118G of the μ opioid receptor alters its N-glycosylation and protein stability. Biochem J (2012) 1.06
Loss of CDKL5 disrupts kinome profile and event-related potentials leading to autistic-like phenotypes in mice. Proc Natl Acad Sci U S A (2012) 1.02
Developmental effects of acute, chronic, and withdrawal from chronic nicotine on fear conditioning. Neurobiol Learn Mem (2012) 1.01
Chronic sazetidine-A at behaviorally active doses does not increase nicotinic cholinergic receptors in rodent brain. J Pharmacol Exp Ther (2012) 0.99
Stress-induced potentiation of cocaine reward: a role for CRF R1 and CREB. Neuropsychopharmacology (2009) 0.99
Pharmacogenomic evaluation of the antidepressant citalopram in the mouse tail suspension test. Neuropsychopharmacology (2006) 0.99
Functional relevance of serotonin 2C receptor mRNA editing in antidepressant- and anxiety-like behaviors. Neuropharmacology (2010) 0.99
CREB gene transcription factors: role in molecular mechanisms of alcohol and drug addiction. Alcohol Clin Exp Res (2005) 0.98
Differential distribution of CREB in the mesolimbic dopamine reward pathway. J Neurochem (2003) 0.96
Behavioral and activity assessment of laboratory mice (Mus musculus) after tail biopsy under isoflurane anesthesia. J Am Assoc Lab Anim Sci (2011) 0.96
Inducible cAMP early repressor regulates corticosterone suppression after tricyclic antidepressant treatment. J Neurosci (2004) 0.93
Augmented responses to morphine and cocaine in mice with a 12-lipoxygenase gene disruption. Psychopharmacology (Berl) (2003) 0.93
Reward sensitization: effects of repeated nicotine exposure and withdrawal in mice. Neuropsychopharmacology (2012) 0.92
Genetic background influences the effects of withdrawal from chronic nicotine on learning and high-affinity nicotinic acetylcholine receptor binding in the dorsal and ventral hippocampus. Psychopharmacology (Berl) (2012) 0.90
Differential effects of acute and repeated citalopram in mouse models of anxiety and depression. Int J Neuropsychopharmacol (2009) 0.89
Selective deletion of a cell cycle checkpoint kinase (ATR) reduces neurogenesis and alters responses in rodent models of behavioral affect. Neuropsychopharmacology (2011) 0.89
Cocaine-related behaviors in mice with deficient gliotransmission. Psychopharmacology (Berl) (2012) 0.88
Galantamine, an acetylcholinesterase inhibitor and positive allosteric modulator of nicotinic acetylcholine receptors, attenuates nicotine taking and seeking in rats. Neuropsychopharmacology (2012) 0.88
Alterations in morphine-induced reward, locomotor activity, and thermoregulation in CREB-deficient mice. Brain Res (2005) 0.87
Regulation of antidepressant activity by cAMP response element binding proteins. Mol Neurobiol (2004) 0.87
Decreased CREB levels suppress epilepsy. Neurobiol Dis (2011) 0.86
Sex differences in response to nicotine in C57Bl/6:129SvEv mice. Nicotine Tob Res (2009) 0.86
Parkinson's disease-like neuromuscular defects occur in prenyl diphosphate synthase subunit 2 (Pdss2) mutant mice. Mitochondrion (2011) 0.85
Increased hippocampal neurogenesis and accelerated response to antidepressants in mice with specific deletion of CREB in the hippocampus: role of cAMP response-element modulator τ. J Neurosci (2013) 0.85
Depressive phenotypes evoked by experimental diabetes are reversed by insulin. Physiol Behav (2011) 0.84
Divergent functional effects of sazetidine-a and varenicline during nicotine withdrawal. Neuropsychopharmacology (2013) 0.84
Requirement for the POZ/BTB protein NAC1 in acute but not chronic psychomotor stimulant response. Behav Brain Res (2007) 0.83
μ-Opioid receptor availability in the amygdala is associated with smoking for negative affect relief. Psychopharmacology (Berl) (2012) 0.82
Activation of α4β2*/α6β2* nicotinic receptors alleviates anxiety during nicotine withdrawal without upregulating nicotinic receptors. J Pharmacol Exp Ther (2014) 0.82
Brain region- and sex-specific alterations in DAMGO-stimulated [(35) S]GTPγS binding in mice with Oprm1 A112G. Addict Biol (2012) 0.82
Enhanced extinction of cocaine seeking in brain-derived neurotrophic factor Val66Met knock-in mice. Eur J Neurosci (2012) 0.80
Chronic sazetidine-A maintains anxiolytic effects and slower weight gain following chronic nicotine without maintaining increased density of nicotinic receptors in rodent brain. J Neurochem (2014) 0.80
Brain monoamines and antidepressant-like responses in MRL/MpJ versus C57BL/6J mice. Neuropharmacology (2012) 0.79
CREB-mediated alterations in the amygdala transcriptome: coordinated regulation of immune response genes following cocaine. Int J Neuropsychopharmacol (2010) 0.77
Translational research in nicotine dependence. Cold Spring Harb Perspect Med (2013) 0.77
Targeted gene mutation of E2F1 evokes age-dependent synaptic disruption and behavioral deficits. J Neurochem (2014) 0.77
Translating basic science to improve pharmacotherapy for nicotine dependence. Nicotine Tob Res (2007) 0.76
Not all stress is equal: CREB is not necessary for restraint stress reinstatement of cocaine-conditioned reward. Behav Brain Res (2013) 0.76
The role of cAMP response element-binding proteins in mediating stress-induced vulnerability to drug abuse. Int Rev Neurobiol (2005) 0.76